BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) CFO Jason Keyes bought 700 shares of the company’s stock in a transaction on Monday, August 10th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $11,200.00. Following the transaction, the chief financial officer directly owned 700 shares in the company, valued at approximately $11,200. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
BlossomHill Therapeutics Stock Up 3.3%
Shares of NASDAQ:BLSM opened at $16.52 on Wednesday. BlossomHill Therapeutics, Inc. has a 12-month low of $15.25 and a 12-month high of $17.25.
Featured Articles
- Five stocks we like better than BlossomHill Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
